-Peracetic Acid Market is projected to reach USD 1,685 million by 2030 Globally, at a CAGR of 7.6%, says MarketsandMarkets™-Escient Pharmaceuticals Announces $120 Million Series C Financing-Fusion Enertech proporciona inversión en litio y soporte técnico de EDL para Argentina-Global Industrial Computers Market Is Expected to Generate $8.9 Billion by 2031: Allied Market Research-Silvano Fashion Group Consolidated Interim Financial Report for Q3 and 9 months of 2022 (unaudited)-Silvano Fashion Group 2022.aasta III kvartali ja 9 kuu konsolideeritud vahearuanne (auditeerimata)-Acciones del banco Santander ¿Buena o mala inversión en dividendos?-Flow Imaging Microscopy Market Size 2022, Industry Saturation, Share, Trends, Market Modification, and Expansion & Revolution Forecast till 2022 to 2032 : Quince Market Insights-Clear Sky Preliminary Data Review Completed by Processing Partner MDS-Report on Financial Results for the Three and Nine Months Ended September 30, 2022-Three Valley Copper Reports 2022 Third Quarter Results-Morgan Stanley Schedules Quarterly Investor Conference Call-Natuzzi S.p.A.: Third Quarter 2022 Financial Results and Shareholder Letter-Avante Logixx Inc. Announces Financial Results For The Second Fiscal Quarter Ended September 30, 2022-Pershing Square Holdings, Ltd. Announces Transactions in Own Shares – 25 November 2022-FEELM construye una fábrica ecológica con un sistema de gestión de la energía que reduce las emisiones de carbono en 500 toneladas-beaconsmind AG Announces the Postponement of the Publication of Its Annual Financial Report to December 16, 2022-Teleperformance SE: Statement on Transactions on Own Shares Carried out from November 18 to November 24, 2022 (inclusive)-The Korea Fund, Inc. Announces Invitation to Join a Webinar-Global Meat Substitutes Market Revenue is Predicted to Reach US$4.0 billion by 2027 – says MarketsandMarkets™

PharmaTher Provides Business Highlights and Releases Audited Annual Financials for Fiscal Year Ended May 31, 2022

| Source: PharmaTher Holdings Ltd.

Nearly $12 million in cash and investment

Fully funded for the Company’s development programs, including ketamine injection and infusion products, ketamine microneedle patch and ketamine wearable pump device for mental health, neurological, and pain disorders

Seeking FDA approval for the Company’s ketamine injection and infusion products for anesthesia and procedural sedation in 2023

TORONTO, Sept. 29, 2022 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders, today released business highlights and audited financial results for its fiscal year ended May 31, 2022. All amounts in this press release are in Canadian dollars. 

Fabio Chianelli, Chief Executive Officer of PharmaTher, said, “We had achieved important clinical and business milestones that will pave the way for PharmaTher to potentially become a commercial-stage company in 2023. With a little over $12 million in cash and investment on our balance sheet, we are in a strong position to advance our ketamine-based clinical development and commercial programs to treat mental health, neurological and pain disorders. To support our commercial objectives, we aim to file abbreviated new drug applications with the FDA for our ketamine injectable products for anesthesia and procedural sedation. We expect to obtain FDA approvals by 2H-2023. Our clinical development objectives for the next twelve months include obtaining FDA agreement to conduct a potential Phase 3 clinical trial evaluating ketamine for Parkinson’s disease, present results from the Phase 2 clinical trial evaluating ketamine for Amyotrophic Lateral Sclerosis, present clinical study results in depression and pain with our ketamine microneedle patch and ketamine wearable pump device, and partner with pharmaceutical companies for our ketamine products, drug delivery systems and clinical programs. Finally, I like to thank the PharmaTher team, our Board of Directors and our shareholders for supporting our objective in unlocking the therapeutic potential of ketamine for unmet medical needs.”

Financial Highlights

  • Cash and cash equivalents ($9,154,906) and Investment ($2,966,667) for a total of $12,121,573 as of May 31, 2022.

Business Highlights

  • Presented Late-Breaking Abstract Presentation of Positive Efficacy and Safety Data from Phase 1/2 Clinical Study of Ketamine in the Treatment of Levodopa-Induced Dyskinesia in Parkinson’s Disease at the MDS International Congress.
  • Granted FDA Orphan Drug Designations For Ketamine To Treat Complex Regional Pain Syndrome and Status Epilepticus.
  • Completed IND-Enabling Pharmacokinetic and Tolerability Study with Ketamine Microneedle Patch.
  • Engaged CCBIO to Develop and Commercialize Novel Ketamine Wearable Delivery Device.
  • Received  FDA Approval of Investigational New Drug Application for Ketamine to Treat ALS.
  • Entered into Process Development Agreement with LTS Lohmann for Ketamine Microneedle Patch.
  • Presented Positive Research Results for LSD Microneedle Patch and Psilocybin Microneedle Patch.
  • Engaged Alcami for Clinical and Commercial Manufacturing for Ketamine.

For further information, please refer to the Company’s audited annual financial statements prepared in accordance with International Financial Reporting Standards and the related management’s discussion and analysis for the financial year ended May 31, 2022, which are available under the Company’s profile on SEDAR at www.sedar.com.

About PharmaTher Holdings Ltd.

PharmaTher Holdings Ltd. (OTCQB: PHRRF) (CSE: PHRM) is a specialty pharmaceutical company focused on developing and commercializing novel uses and delivery forms of ketamine to treat mental health, neurological and pain disorders. PharmaTher’s product portfolio consists of KETARX™ (ketamine) delivered by intravenous injection, intradermal microneedle patch, and subcutaneous pump administration. Learn more at PharmaTher.com.

For more information about PharmaTher, please contact:

Fabio Chianelli

Chief Executive Officer

PharmaTher Holdings Ltd.

Tel: 1-888-846-3171

Email: info@pharmather.com

Website: www.pharmather.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.

Cautionary Statement

This press release contains ‘forward-looking information’ within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated”, “potential”, “aim”, “may” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on PharmaTher Holdings Ltd. (the “Company”) current belief or assumptions as to the outcome and timing of such future events. Forward-looking information is based on reasonable assumptions that have been made by the Company at the date of the information and is subject to known and unknown risks, uncertainties, and other factors that may cause actual results or events to differ materially from those anticipated in the forward-looking information. Given these risks, uncertainties and assumptions, you should not unduly rely on these forward-looking statements. The forward-looking information contained in this press release is made as of the date hereof, and Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required by applicable securities laws. The foregoing statements expressly qualify any forward-looking information contained herein. Factors that could cause actual results to differ materially from those anticipated in these forward-looking statements are described under the caption “Risk Factors” in Company’s management’s discussion and analysis for the fiscal year ended May 31, 2022 (“MD&A”), dated September 28, 2022, which is available on the Company’s profile at www.sedar.com.

This news release does not constitute an offer to sell or the solicitation of an offer to buy, and shall not constitute an offer, solicitation or sale in any state, province, territory or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state, province, territory or jurisdiction.

Leave a Comment